Figures computed from official regulatory filings — .
Ownershipinsiders 6.43% · institutions 0%
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for PetLife Pharmaceuticals, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States. The company's principal product is Vitalzul that inhibits blood vessels formation in solid tumors. It is also developing Vitalzul as a prescription strength oral pharmaceutical, as well as a concentrated intravenous and injectable version for direct administration to a tumor. In addition, the company develops edible dog and cat treats. Petlife Pharmaceuticals, Inc. is based in Los Angeles, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
9 buys1 sell— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Campbell Vyvyantrack record | Buy | $1.2B | conv 70 |
| SEC |
| Vivek Ramana | Award | $670K | SEC |
| Vivek Ramana | Other | n/a (No price was disclosed in the filing) | SEC |
| Vivek Ramana | Other | n/a (No price was disclosed in the filing) | SEC |
| Salvagno Ralph T | Award | $300K | SEC |
| Salvagno Ralph T | Other | n/a (No price was disclosed in the filing) | SEC |
| Campbell Vyvyantrack record | Other | n/a (No price was disclosed in the filing) | SEC |
| Salvagno Ralph T | Other | n/a (No price was disclosed in the filing) | SEC |
| Campbell Vyvyantrack record | Other | n/a (No price was disclosed in the filing) | SEC |
| Salvagno Ralph T | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Salvagno Ralph T | Buy | $25K | conv 53First in 12mo | SEC |
| Salvagno Ralph T | Buy | $248.4K | conv 63 | SEC |
| Salvagno Ralph T | Buy | $160K | conv 63 | SEC |
| Salvagno Ralph T | Buy | $160K | conv 40 | SEC |
| Salvagno Ralph T | Award | $5.6M | SEC |
| Campbell Vyvyantrack record | Buy | $25K | conv 71 | SEC |
| Campbell Vyvyantrack record | Award | $4.7M | SEC |
| Campbell Vyvyantrack record | Award | $600K | SEC |
| Campbell Vyvyantrack record | Buy | $37.7K | conv 27First in 12mo | SEC |
| Campbell Vyvyantrack record | Buy | $10K | conv 11 | SEC |
| Campbell Vyvyantrack record | Buy | $273.1K | conv 54 | SEC |
| WHITE CURT C | Sell | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |